Last reviewed · How we verify
Terazosin therapy
Terazosin therapy is a Small molecule drug developed by Cedars-Sinai Medical Center. It is currently in Phase 2 development.
Terazosin is a small molecule that acts as an adrenergic receptor alpha-1 antagonist. It is used to treat conditions such as disorders of the urinary stent, and has been studied in clinical trials for other conditions including Parkinson's disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Terazosin therapy |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Terazosin for Dementia With Lewy Bodies (PHASE1, PHASE2)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
- Terazosin and Parkinson's Disease Extension Study (PHASE2)
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage (PHASE3)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke (PHASE3)
- A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
- Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terazosin therapy CI brief — competitive landscape report
- Terazosin therapy updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI
Frequently asked questions about Terazosin therapy
What is Terazosin therapy?
Who makes Terazosin therapy?
What development phase is Terazosin therapy in?
Related
- Manufacturer: Cedars-Sinai Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing